Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term

被引:11
|
作者
Chen, Liqi [1 ]
Li, Guoli [1 ]
Li, Jieshou [1 ]
Fan, Chaogang [1 ]
Xu, Jian [2 ]
Wu, Bo [3 ]
Liu, Kun [1 ]
Zhang, Caihua [4 ]
机构
[1] Nanjing Univ, Dept Surg, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu, Peoples R China
[2] Nanjing Univ, Dept Med Imaging, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu, Peoples R China
[3] Nanjing Univ, Dept Pathol, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu, Peoples R China
[4] Xuzhou Cent Hosp, Xuzhou, Peoples R China
关键词
Gastric cancer; Preoperative chemotherapy; ERCC1; TS; Endarterial-intravenous coadministration; Real-time Fluorescent quantitative PCR; THYMIDYLATE SYNTHASE; NEOADJUVANT CHEMOTHERAPY; DIHYDROPYRIMIDINE DEHYDROGENASE; PERIOPERATIVE CHEMOTHERAPY; CISPLATIN; SURVIVAL; 5-FLUOROURACIL; PREDICTION; REGRESSION; GENE;
D O I
10.1007/s00280-013-2083-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To study the correlation between expression levels of ERCC1/TS mRNA and the susceptibility of preoperative chemotherapy for patients with gastric cancer. A total of forty cases with advanced gastric cancer of T3-4N1-2M0 were treated with preoperative chemotherapy according to FLEEOX regimen based on endarterial-intravenous coadministration. Sufficient, fresh gastric tissue specimens were obtained with the help of gastroscope, and the expression levels of ERCC1/TS mRNA were detected by qRT-PCR before chemotherapy. The chemotherapeutic response was evaluated with Choi Criteria after chemotherapy, and pathologic remission extent was observed after surgery. The correlation between the expression levels of ERCC1/TS mRNA before chemotherapy and the chemotherapeutic effect based on imageology and pathology was analyzed. The response rate of Chemotherapy in this cohort was 80.0 % based on imageology and 51.43 % based on pathology. The expression levels of ERCC1/TS mRNA were significantly associated with imageology remission extent (P = 0.033, P = 0.025) and pathologic remission extent (P = 0.044, P = 0.016), respectively. The chemotherapeutic effect on patients with low-expression levels of ERCC1/TS mRNA was better. From the perspective of pathology and imageology evaluating the preoperative chemotherapeutic response for patients with gastric cancer, ERCC1 and TS were used as the molecular predictors and provided prognostic information in this study.
引用
收藏
页码:921 / 928
页数:8
相关论文
共 50 条
  • [21] Prognostic Impact of ERCC1 Gene Polymorphisms in Gastric Cancer
    Metzger, Ralf
    Warnecke-Eberz, Ute
    Bollschweiler, Elfriede
    Brabender, Jan
    Vallbohmer, Daniel
    Hoelscher, Amulf H.
    GASTROENTEROLOGY, 2009, 136 (05) : A920 - A920
  • [22] Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
    Lu, Zheng-mao
    Luo, Tian-hang
    Nie, Ming-ming
    Fang, Guo-en
    Ma, Li-ye
    Xue, Xu-chao
    Wei, Guo
    Ke, Chong-we
    Bi, Jian-wei
    TUMOR BIOLOGY, 2014, 35 (04) : 2941 - 2948
  • [23] Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy
    Zhang, Y. Y.
    Gu, K. S.
    Wu, H. Y.
    Yang, F.
    Bu, L. J.
    Zhao, C. C.
    Zhang, Y. R.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04): : 15921 - 15929
  • [24] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    Sara De Dosso
    Elena Zanellato
    Martina Nucifora
    Renzo Boldorini
    Angelica Sonzogni
    Roberto Biffi
    Nicola Fazio
    Eraldo Bucci
    Ottavio Beretta
    Stefano Crippa
    Piercarlo Saletti
    Milo Frattini
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 159 - 165
  • [25] ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy
    Wei, J.
    Liu, B.
    Zou, Z.
    Qian, X.
    Zhang, W.
    Yu, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer
    Huang, Zhao-Hui
    Hua, Dong
    Du, Xiang
    Li, Li-Hua
    Mao, Yong
    Liu, Zhi-Hui
    Song, Ming-Xu
    Zhou, Xi-Ke
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (41) : 6401 - 6407
  • [28] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    De Dosso, Sara
    Zanellato, Elena
    Nucifora, Martina
    Boldorini, Renzo
    Sonzogni, Angelica
    Biffi, Roberto
    Fazio, Nicola
    Bucci, Eraldo
    Beretta, Ottavio
    Crippa, Stefano
    Saletti, Piercarlo
    Frattini, Milo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 159 - 165
  • [29] ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy
    Qin, Xiuguang
    Yao, Wenjian
    Li, Weiwei
    Feng, Xianjun
    Huo, Xiaoqing
    Yang, Shujuan
    Zhao, Hui
    Gu, Xiaomeng
    TUMOR BIOLOGY, 2014, 35 (05) : 4697 - 4704
  • [30] The correlation between ERCC1 expression and outcome of chemotherapy in patients with advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group study (DCCG)
    Koopman, M.
    Venderbosch, S.
    Antonini, N. F.
    van Krieken, J. H.
    Punt, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)